2morrow, a digital health startup that developed a clinically validated smoking cessation app to support a six month program, forged a partnership with GlaxoSmithKkine to improve access to its nicotine replacement therapy.
SmartQuit users who are using the app as part of an employer program will receive nicotine replacement therapy as part of their regimen.
In a statement from 2morrow Co-founder and COO Jo Masterson, employers, states, and health plans that choose GSK’s Nicoderm CQ Patch option will get easier access to the patches. Smokers will be able to order the patches from the app and the patches will be shipped to them at home.
presented by
The Healthcare Payments Industry Faces a Perception Challenge
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
The deal is designed to get clear the step of having to go to a physician to get a prescription for the patches. After they complete a quit plan, smokers can order the patches free as long as their employer or health plan offers it.
A randomized controlled trial of its six month program, which uses acceptance and commitment therapy, achieved a 13 percent quite rate compared with 8 percent from a program by Tobacco Control Research division of the National Cancer Institute.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Smokers create a personal plan. They identify triggers that lead them to smoke and learn new ways to deal with those urges, rather than ignoring them. It achieved.
2Morrow’s app is being evaluated as part of a second, larger national clinical trial expected to recruit 1,600 participants. Last year, it received $3.1 million, five-year grant from the National Cancer Institute. The funding would be used in part to update the app ahead of the trial.
Photo: Flickr user Qfamily